Scientists at Nagoya University in Japan studied what happens when macrophages—a type of immune cell—encounter dying cancer cells in tumors and discovered a mechanism that accelerates tumor ...

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterize the diversity of individual cells within ...

Chimeric antigen receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their cancer. One of the limitations of CAR-T ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment ...

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

Discover 8 ways mast cell activation syndrome causes widespread symptoms from digestive issues to brain fog, often mistaken for other conditions.

The U.S. Food and Drug Administration has approved vimseltinib for adult patients with a rare condition called tenosynovial giant cell tumor, based on a trial led by an MSK researcher.

Ultimately, her research led to mast cell activation syndrome, or MCAS, a condition in which mast cells (a type of white blood cell) overreact for reasons that aren’t always clear.

Researchers assessed the rate of patients with basal cell carcinoma and squamous cell carcinoma who had residual histologic tumor at the time of Mohs micrographic surgery.

Mast cell activation syndrome (MCAS) is a condition where the mast cells are inappropriately triggered.

The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy, especially the risk of T-cell neoplasms related to viral vector integration, is an emerging concern.